Investigating a new regulator of T cell immunity
Official title: ATP1B3: novel regulator of T cell-mediated immunity
Funded at New York University School of Medicine · NIH-10978904 · Data updated 2026-11-12
This study is looking at how certain channels in T cells, which help our immune system fight infections and diseases, work and how they might be used to create better treatments for autoimmune and inflammatory conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 15, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $594,452 |
| NIH project number | 1R01AI180128-01A1 |
| Project ID | NIH-10978904 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with autoimmune diseases or those experiencing immune system dysfunction.
✕Less likely to help
Patients with non-autoimmune related conditions or those not experiencing immune system issues may not benefit from this research.
What this research studies
This research focuses on understanding how specific ion channels, particularly the sodium-potassium ATPase, influence the function of T cells, which are crucial for immune responses against infections and autoimmune diseases. By conducting functional genetics screens, the researchers aim to identify previously unrecognized ion channels that regulate T cell activity. This could lead to new therapeutic targets for treating autoimmune and inflammatory conditions, as current treatments do not effectively target these channels. The approach combines genetic analysis with insights into cellular processes to uncover potential drug targets.
Why it matters
Potential benefit: If successful, this research could lead to the development of new treatments for autoimmune diseases by targeting ion channels in T cells.
How similar studies have gone: While the specific approach of targeting ion channels in T cells is relatively novel, there is evidence that similar strategies have been successful in other areas of medicine, particularly in treating cardiovascular and neuropsychiatric disorders.
Where this research is happening
-
New York University School of Medicine
New York, United States Active
Researchers
- Principal investigator: Feske, Stefan — New York University School of Medicine
- Study coordinator: Feske, Stefan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.